Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently ...

AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in the West. The Japanese Ministry of ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge It will grow to $50.99 billion in 2029 at a compound annual ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...

Several factors are driving this expansion, including rising cancer ... AstraZeneca PLC (NASDAQ: AZN). Grand View Research continued: “The increasing prevalence of life-threatening conditions and the ...